Dual Peroxisome Proliferator-Activated Receptor  /  Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Thiazolidinediones and PPARγ agonists: time for a reassessment

(2012) Bertrand Cariou et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Effects of the New Dual PPAR /  Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism

(2011) B. Cariou et al.   DIABETES CARE

Mechanism of Action of a Peroxisome Proliferator-Activated Receptor (PPAR)-δ Agonist on Lipoprotein Metabolism in Dyslipidemic Subjects with Central Obesity

(2011) Esther M. M. Ooi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin

(2011) Harold E. Bays et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults

(2011) Bertrand Cariou et al.   Nutrition & Metabolism

The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact

(2011) Esther Phielix et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects

(2010) Stefano Rizza et al.   ATHEROSCLEROSIS

Pharmacological management of type 2 diabetes: the potential of incretin-based therapies

(2010) B. Charbonnel et al.   DIABETES OBESITY & METABOLISM

Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease

(2010) Elisa Fabbrini et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome

(2010) Renata Belfort et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate

(2009) Marja-Riitta Taskinen et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Genomics of type 2 diabetes mellitus: implications for the clinician

(2009) Elliot S. Stolerman et al.   Nature Reviews Endocrinology

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

(2008) Vlad Ratziu et al.   GASTROENTEROLOGY

Rosiglitazone Reduces Liver Fat and Insulin Requirements and Improves Hepatic Insulin Sensitivity and Glycemic Control in Patients with Type 2 Diabetes Requiring High Insulin Doses

(2007) Leena Juurinen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM